(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 October 2018 (25.10.2018)

WIPO | PCT

(10) International Publication Number
WO 2018/195165 A8

(51) International Patent Classification:
A61K 39/12 (2006.01) *C12N 15/86* (2006.01)
A61K 31/713 (2006.01) *A61P 31/20* (2006.01)
C12N 15/113 (2010.01) *A61K 39/00* (2006.01)

(21) International Application Number:
PCT/US2018/028116

(22) International Filing Date:
18 April 2018 (18.04.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/486,618	18 April 2017 (18.04.2017)	US
62/553,358	01 September 2017 (01.09.2017)	US
62/646,978	23 March 2018 (23.03.2018)	US
62/655,862	11 April 2018 (11.04.2018)	US

(71) Applicants: **ALNYLAM PHARMACEUTICALS, INC.** [US/US]; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US). **TECHNISCHE UNIVERSITÄT MÜNCHEN** [DE/DE]; Arcisstrasse 21, 80333 Munich (DE).

(72) Inventors: **SEPP-LORENZINO, Laura**; 300 Third Street, 3rd Floor, Cambridge, MA 02142 (US). **PROTZER, Ulrike**; Trogerstrasse 30, 81675 Munich (DE). **MICHLER, Thomas**; Trogerstrasse 30, 81675 Munich (DE).

(74) Agent: **SARGEANT, Brooke** et al.; Seed Intellectual Property Law Group LLP, 701 Fifth Avenue, Suite 5400, Seattle, Washington 98104-7092 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:
22 November 2018 (22.11.2018)

(15) Information about Correction:
see Notice of 22 November 2018 (22.11.2018)

(54) Title: METHODS FOR THE TREATMENT OF SUBJECTS HAVING A HEPATITIS B VIRUS (HBV) INFECTION

(57) Abstract: The present invention provides methods for the treatment of a subject having a Hepatitis B virus (HBV) infection, e.g., a chronic HBV infection, using a combination of an RNAi agent that targets HBV and an HBV vaccine. It is disclosed a RNAi agent and an HBV vaccine for use in treatment of HBV infection, comprising sequentially administering to the subject having an HBV infection: a) an RNAi agent that inhibits expression of at least three HBV transcripts, wherein the RNAi agent forms a double stranded region; b) a protein-based vaccine comprising a first HBV core antigen (HBcAg) polypeptide, and a first HBV surface antigen (HBsAg) polypeptide; and c) a nucleic acid-based vaccine comprising an expression vector construct encoding a second HBcAg polypeptide, and/or a second HBsAg polypeptide, wherein the second HBcAg polypeptide, and/or the second HBsAg polypeptide, shares at least one epitope with at least one of the first HBcAg polypeptide, and/or the first HBsAg polypeptide.

WO 2018/195165 A8